NNIT NNIT A/S

NNIT A/S: NNIT adjusts 2025 outlook and publishes Q1 figures

NNIT A/S: NNIT adjusts 2025 outlook and publishes Q1 figures

The first quarter financial performance was expected to be moderate, but the increased macroeconomic and geopolitical uncertainty has impacted NNIT to a larger extent than expected. Based on the realized results and the continued uncertainty, NNIT adjusts the 2025 financial outlook.

Given the current uncertainty, organic revenue growth is expected to be 0% to 5% (previously 7% to 10%), which is due to postponement of projects and the sales pipeline materializing at a slower pace than planned as customers are hesitating to engage in new contracts, especially within Life Science. Expectations for the Group operating profit margin excluding special items are maintained at 7% to 9% as NNIT is significantly reducing its cost base by adjusting capacity and lowering general spending across regions and on corporate level. Special items are expected to be up to last year’s level of DKK 69m (previously expected to be below the 2024 level) mainly driven by further restructuring costs.

NNIT generated Q1 2025 Group revenue of DKK 464m (Q1 2024: DKK 463m). The organic growth was negative by 0.8% (Q1 2024: 8.0%) due to Region Europe and Region US. Group operating profit excl. special items was DKK 18m (Q1 2024: 24m), equal to a margin of 3.9% (Q1 2024: 5.2%). Profit and margin were mainly impacted by Region Europe and a decrease in Region Denmark driven by overcapacity following the postponement of a large contract, which has been signed in Q2, and the loss of a large public tender. Special items for the Group amounted to DKK 25m (Q1 2024: income DKK 11.3m) primarily driven by restructuring costs.

Financial figures, DKK millionQ1 2025Q1 2024FY 2024
GROUP   
Revenue464463 1,851
Group operating profit excl. special items1824117
Group operating profit margin excl. special items3.9%5.2%6.3%
Special items25-1169
    
REGION EUROPE   
Revenue119126512
Regional operating profit121467
Regional operating profit margin10.0%11.2%13.0%
    
REGION US   
Revenue8793346
Regional operating profit261873
Regional operating profit margin30.4%19.0%21.2%
    
REGION ASIA   
Revenue3732149
Regional operating profit3-28
Regional operating profit margin7.6%-5.3%5.2%
    
REGION DENMARK   
Revenue221212844
Regional operating profit3348151
Regional operating profit margin15.1%22.6%17.9%



Despite the adjustment of expectations for organic growth, NNIT maintains expectations for the Group operating profit margin excl. special items to reach 7% to 9%. NNIT has executed several cost reducing initiatives, which include capacity adjustments across the group, to minimize the impact on profitability.

NNIT will publish the Q1 2025 trading statement on May 5, 2025, one day earlier than planned.

For more information, please contact:

Investor Relations

Carsten Ringius            

EVP & CFO

Tel:

Media Relations

Thomas Stensbøl

Press & Communications Manager

Tel:

 

ABOUT NNIT

NNIT is a leading provider of IT solutions to life sciences internationally, and to the public and private sectors in Denmark.

We focus on high complexity industries and thrive in environments where regulatory demands and complexity are high.

We advise on and build sustainable digital solutions that work for the patients, citizens, employees, end users or customers.

We strive to build unmatched excellence in the industries we serve, and we use our domain expertise to represent a business first approach – strongly supported by a selection of partner technologies, but always driven by business needs rather than technology.

NNIT consists of group company NNIT A/S and the subsidiary SCALES. Together, these companies employ more than 1,700 people in Europe, Asia and USA.

Attachment



EN
05/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NNIT A/S

 PRESS RELEASE

NNIT A/S: NNIT shares its financial calendar for 2026

NNIT A/S: NNIT shares its financial calendar for 2026 The financial calendar for 2026: 28 January 2026Deadline for shareholder proposals for the Annual General Meeting5 February 2026Interim Financial Report Q4 2025 and Annual Report 202512 March 2026Annual General Meeting12 May 2026Interim Financial Report Q1 202627 August 2026Interim Financial Report H1 20265 November 2026Interim Financial Report Q3 2026 For more information, please contact: Investor RelationsCarsten RingiusEVP & CFOTel: Media RelationsThomas StensbølPress & Communications ManagerTel: ABOUT NNIT NNIT is a leadi...

ABGSC IT Research ... (+2)
  • ABGSC IT Research
  • Mikkel Kousgaard Rasmussen
ABGSC IT Research ... (+2)
  • ABGSC IT Research
  • Mikkel Kousgaard Rasmussen
 PRESS RELEASE

NNIT A/S: On-track performance with doubled profitability

NNIT A/S: On-track performance with doubled profitability Q3 2025 key highlights While business was still being negatively impacted by macroeconomic and geopolitical uncertainty, there was an uplift in financial performance in the third quarter. Group operating profit excluding special items more than doubled at DKK 35.6m, corresponding to a margin of 8.2% against 3.9% in the third quarter of 2024. The step-change in margin development compared with last quarter and last year was driven by more efficient operations in terms of improving utilization and the effect from cost reducing initiat...

 PRESS RELEASE

NNIT A/S: NNIT restates its life science segment in its financial repo...

NNIT A/S: NNIT restates its life science segment in its financial reporting structure Today, NNIT announces an update to its financial reporting structure to ensure that all Life Sciences customers are fully consolidated under Region Europe, US, and Asia. As a result, all Life Science customers previously reported under Region Denmark irrespective of the business activity will now be included in Region Europe’s profit and loss statement. Going forward, Region Denmark will consist solely of the Public segment and the Private segment, which includes SCALES. The restatement of the Life Scienc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch